NSCLC

May 09, 2025

ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...

May 09, 2025

Lung cancer remains the leading cause of cancer-related death in the United States; approximately 85% of lung cancers are non-small cell lung cancer (NSCLC), with ~530K cases in the 7MM. The main subtypes of NSCLC are adenocarcinoma (~57%), squamous cell carcinoma (~26%), and large cell carcinoma (~2%). Despite adv...

Apr 28, 2025

The European Lung Cancer Congress (ELCC) 2025, which took place in Paris from March 26-29, 2025, brought together lung cancer experts who presented the most anticipated clinical results. The three days served as an essential platform for exchanging valuable insights and fostering connections within the lung cancer ...

Mar 28, 2025

Non-small cell lung cancer (NSCLC) remains one of the toughest cancers to treat, but bispecific antibodies (BsAbs) are changing the game. Unlike traditional therapies, BsAbs are engineered to target two different antigens simultaneously, enhancing precision and boosting immune response. This dual-targeting approach...

Dec 13, 2024

AstraZeneca has secured another approval for its cancer blockbuster IMFINZI (durvalumab), as the FDA has approved the PD-L1 inhibitor for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent chemotherapy and radiation. This approval makes IMFINZI the ...

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 500K cases in the 7MM were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year. Analysis indicates that the most common ge...

Nov 29, 2024

Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...

Nov 29, 2024

The treatment options for  Non-Small Cell Lung Cancer (NSCLC) have been flooded in recent years due to improved methods of molecular profiling and better diagnostic tools. The new molecular biomarkers, with their efficacious treatments for NSCLC, have changed the lives of patients where the clinical prognosis was v...

Nov 29, 2024

Lung cancer was the most prevalent cancer globally, with 2.5 million new cases, representing 12.4% of all new cancer diagnoses. NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. As per the latest estimates, the total incident cases of NSCLC in the 7MM were approximately 500K cases ...

Nov 29, 2024

According to the World Health Organization (WHO), in 2022, there were approximately 2.5 million new cases of lung cancer globally, which accounted for 12.4% of all newly diagnosed cancer cases. Lung cancer continues to be one of the most common and deadly malignancies worldwide, with significant contributions to gl...